Why BGPT?
logo

Review Claim by Claim

Check what supports each statement: experiments, reported results, scope, and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to review paper



    Explore by Goal












     Quick Explanation


    High-level verdict: This is a high-quality precision-imaging data descriptor (N=7 healthy adults) that (a) provides an openly-shared, densely sampled multi-modal fMRI + diffusion dataset acquired during psilocybin and methylphenidate exposures, (b) shows acute desynchronization and transient modularity reductions on psilocybin, and (c) supplies rich, reusable raw and processed data on OpenNeuro — but conclusions about mechanisms or therapeutic generality are limited by small sample size, demographic homogeneity, partial physiological coverage, and possible vascular confounds that require multimodal validation



     Long Explanation


    Visual paper analysis — Psilocybin’s acute and persistent brain effects: a precision imaging drug trial (10.1038/s41597-025-05189-0)

    Visualize first — data provenance, key numbers, then concise critique. All claims below are cited to primary sources with detailed extracts.

    Dataset
    OpenNeuro ds006072: raw, minimally preprocessed, and processed multi-echo fMRI, structural, diffusion (DBSI), physiological traces, and behavioral measures (MEQ, Mini-IPIP).
    Source:
    Primary imaging observations
    Acute psilocybin produced network desynchronization and a robust transient decrease in network modularity; persistent hippocampus–DMN decoupling observed up to ~3 weeks.
    See authors' analytic claims and follow-up medRxiv summary:
    Key limitations
    Small N (7), demographic homogeneity (6 Caucasian), physiological traces incomplete (subset), potential vascular/neurovascular confounds for BOLD under 5-HT2A agonism, and limited clinical population generalizability.
    Vascular confound references: mouse work showing psilocybin alters neurovascular coupling and extends haemodynamic responses, which can artifically affect BOLD FC measures

    Critical appraisal (evidence-based, skeptical)

    • Strength — data sharing & methods: exemplary: multi-echo EPI, NORDIC denoising, FIRMM, PhysIO, DBSI diffusion — increases SNR and reproducibility potential
    • Weakness — sample size & generalizability: N=7 is suitable for PFM-style within-subject mapping but underpowered for population-level inference; demographic homogeneity (majority Caucasian) reduces external validity.
    • Confound risk — vascular/neurovascular coupling: Preclinical evidence indicates psilocybin can alter NVC and BOLD dynamics; BOLD-only fMRI may conflate vascular and neural changes unless complemented by direct neuronal measures (EEG/MEG/PET) or vascular modeling
    • Behavioral linkage: Strong within-subject correlation between subjective mystical-type scores (MEQ30) and individual network changes is plausible, but causality remains unproven — replication in larger cohorts and mediator analyses are needed
    • Reproducibility: Excellent potential: all raw data and preprocessing code shared; nevertheless small N and complex preprocessing choices (multi-echo combination, censoring thresholds) mean re-analyses could yield different effect sizes — good for methods development and hypothesis generation but not definitive population estimates.

    Context in the field

    This dataset and descriptor extend prior human psilocybin imaging (e.g., small open-label fMRI reports of lasting connectivity changes and reduced amygdala reactivity) by applying precision functional mapping and dense sampling, which better isolates intra-subject signals but preserves the fundamental limitation: small subject numbers in human psychedelic neuroimaging

    Reproducibility & reuse checklist

    1. Data location: OpenNeuro ds006072; BIDS-organized with session notes (PPFM_session_notes.xlsx) and behavioral CSVs — ready for re-analysis
    2. Key preprocessing steps documented: NORDIC, multi-echo weighted summation, top-up distortion correction, motion censoring FD>0.30 mm, tissue regression, temporal filter 0.009-0.08 Hz.
    3. Recommended additional analyses for users reusing data: (a) include physiological regressors and explicit NVC modeling; (b) run BOLD–CBV/CBF-sensitive analyses where possible; (c) perform model comparisons across multi-echo combination strategies; (d) re-run modularity and FC effects with alternative censoring thresholds to assess robustness.

    Falsifiability — what would change the conclusions?

    • If a larger, randomized, double-blinded sample (N>50) failed to observe acute modularity decreases or hippocampus–DMN decoupling after controlling for vascular/NVC effects, the dataset's interpretive claims about persistent circuit-level changes would be weakened.
    • If multimodal measurements (simultaneous EEG/MEG or calibrated fMRI, or PET/neurovascular measures) show that BOLD desynchronization is driven primarily by vascular prolongation rather than by neuronal desynchronization, the neurophysiological interpretation would need revision — see mouse NVC evidence

    Key source extracts (detailed)

    Practical recommendations for researchers reusing the data

    • Re-analyze with explicit hemodynamic modeling: convolve neural regressors with individual-specific HRFs or use deconvolution to reduce vascular bias.
    • Combine with non-BOLD modalities where possible (EEG/MEG/PET) to dissociate vascular vs neuronal effects.
    • Perform sensitivity analyses across motion-censoring thresholds, multi-echo combination weighting, and inclusion/exclusion of physiological regressors to test robustness of modularity/FC effects.
    • Use the dataset to train procedures for individualized network mapping under pharmacological perturbation (PFM), then test replicability in larger cohorts.


    Feedback:    

    Updated: March 11, 2026

     BGPT Paper Review


    Study Novelty

    90%

    The dataset applies precision functional mapping (dense repeated within-subject sampling + multi-echo imaging + advanced denoising) to an acute psychedelic pharmacology study — a methodological advance over prior small open-label fMRI reports and valuable as a public resource for mechanistic re-analysis.


    Scientific Quality

    80%

    High technical rigor (multi-echo, NORDIC denoising, FIRMM motion monitoring, physiological regressors, BIDS/OpenNeuro sharing) and transparent code release support quality; key limitations are small N, partial physiological coverage, demographic homogeneity, and interpretive risk from vascular confounding (addressable but not fully resolved). No obvious prompt-injection or manipulation attempts detected; COI statements are transparent.


    Study Generality

    70%

    Within-subject PFM produces rich individual-level mechanistic signals that generalize to methods and hypotheses in human neuropharmacology, but small sample and healthy-only participants limit generalization to clinical populations and population-average effect estimates.


    Study Usefulness

    80%

    Very useful as an open, richly annotated dataset for methods development, replication attempts, and hypothesis generation about psilocybin effects; less useful alone for establishing clinical efficacy or population-level neural biomarkers without larger confirmatory cohorts.


    Study Reproducibility

    80%

    Data and code are publicly available (OpenNeuro ds006072; GitLab repo), preprocessing steps comprehensively described, and BIDS formatting used; small sample and complex denoising choices (NORDIC, multi-echo combination weights, censoring thresholds) mean re-analyses could change effect sizes, but reproducibility of methods is high.


    Explanatory Depth

    70%

    Provides mechanistic candidate findings (acute desynchronization; hippocampus–DMN decoupling) and links subjective experience to network-level changes, but does not fully disentangle vascular vs neuronal BOLD effects or provide causal neuronal measures — deeper mechanistic claims require multimodal corroboration and larger samples.


    🎁 Authors: Collect 451 Free Science Tokens (≈ $45.1 USD)

    Claim My Author Tokens

    Use for 112 days of free BGPT access (4 tokens = 1 day) or trade/sell (≈ $45.1 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    Loading OpenNeuro ds006072 BIDS derivatives, computing parcelwise FC matrices across sessions, and performing mixed-effects modularity comparisons to reproduce reported modularity decreases and test sensitivity to motion and physiological regressors.



     Hypothesis Graveyard


    Pure 'global neuronal excitation' hypothesis: discounted because multi-echo and modularity measures show regionally specific desynchronization rather than uniform excitation; animal electrophysiology demonstrates desynchronization patterns and changed phase-locking (not uniform excitation)


    Sole vascular artifact hypothesis: unlikely as a total explanation because subjective-FC correlations and replication of PSIL–PSIL similarity across participants suggest shared neurophysiological components; however, vascular effects likely contribute significantly and must be modeled explicitly (see mouse NVC findings)

     Science Art


    Paper Review: Psilocybin’s acute and persistent brain effects: a precision imaging drug trial Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending